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Abstract The relationship between matrix metalloproteinase
(MMP ) polymorphisms and bladder cancer risk has become a
hot topic and was studied extensively in recent years, but the
results are still controversial. In order to estimate the relation-
ship of MMP polymorphisms and the risk of bladder cancer,
we performed this meta-analysis.We conducted a comprehen-
sive search of databases; PubMed, Web of Science, Embase,
Chinese Biomedical Literature Database (CBM, Chinese) and
Wanfang Database (Chinese) were searched for all case–con-
trol studies which mainly study the relationship between
MMP-1 -1607 1G/2G, MMP-2 -1306 C/T, and MMP-9 -1562
C/T polymorphisms and the susceptibility of bladder cancer.
The association between the MMP polymorphisms and blad-
der cancer risk was conducted by odds ratios (ORs) and 95 %
confidence intervals (95 % CIs). At last, totally five literatures
with 1,141 cases and 1,069 controls were contained in the
meta-analysis. Among these articles, four articles with 1,103
cases and 1,053 controls were about MMP-1-1607 1G/2G
polymorphism and three studies with 839 cases and 775
controls for MMP-2 -1306 C/T polymorphism and MMP-9 -
1562 C/T polymorphism. With regard to MMP-1 -1607 1G/
2G polymorphism, significant association was found with
bladder cancer susceptibility only under recessive model
(2G2G vs. 1G2G/1G1G: OR=1.44, 95 % CI=1.05–1.97,
P =0.022), and as to the MMP-2 -1306 C/T polymorphism,
significant association was found with bladder cancer suscep-
tibility only under homozygote model (TT vs. CC: OR=2.10,
95 % CI=1.38–3.10, P =0), but no associations was found
betweenMMP-9-1562 C/T polymorphism and bladder cancer
susceptibility. The results suggest that the MMP-2-1306 C/T
andMMP-9-1562 C/T polymorphisms are significantly asso-
ciated with bladder cancer susceptibility, and no associations
were found between MMP-9 -1562 C/T polymorphism and
bladder cancer susceptibility.
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Introduction
Bladder cancer is one of the most commonmalignant diseases
around the world that has the highest recurrence rate of any
malignancy [1–3]. The most common type of bladder cancer
is transitional cell carcinomas, and the remainders are squa-
mous tumors, adenocarcinomas, and other subtypes [4]. Its
occurrence increases with age, and it is greater in men. Al-
though there have been increasingly intensive researches on
bladder cancer over the past several decades, there are little
advances in the understanding of the pathogenesis of bladder
cancer [2, 5]. Previous studies have reported that several
environmental factors may be considered as the risk to bladder
cancer, for instance of smoking, chronic inflammation, anti-
cancer drugs, aromatic amines contained in dyes, radiation
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exposure, and so on [6, 7]. However, many people exposed to
these risk factors do not develop bladder cancer, while among
those people not exposed to the risk factors listed above, a
large number of patients develop bladder cancer, and this
suggests that in addition to environmental factors, genetic
factors may play an important role in the development of
bladder cancer [8, 9]. Host factors, such as genetic polymor-
phisms, have been reported as a risk factor in the development
of cancers; bladder cancer is one of the cancers [10–12].
Previous studies have reported that genetic variants in
genes encoding proteins like matrix metalloproteinase
(MMP ) enzymes may contribute to the development of blad-
der cancer [13, 14]. MMP is a family of matrix metallopro-
teinases and a zinc-dependent endopeptidase enzyme that can
reduce substantially all of the extracellular matrix components
such as basement membrane, collagen, and fibronectin
[15–17].MMPs play an important role not only in physiolog-
ical but also in pathological conditions, including tissue re-
generation, wound repair, reproduction, arthritis, atheroscle-
rosis, and so on [18]. The MMP-1 , MMP-2 , and MMP-9
genes are three important members of the MMP family. The
polymorphisms of MMP-1-1607 1G/2G, MMP-2 -1306 C/T,
and MMP-9 -1562 C/T were reported to be related with blad-
der cancer susceptibility, but the conclusions remain to be
inconsistent [13, 19–23]. So, to get a more accurate result,
we conducted this meta-analysis.
Materials and methods
Publication search
We conducted a comprehensive search strategy through
searching the electronic databases, such as the PubMed,
Web of Science, Embase, Chinese Biomedical Literature
Database (CBM, Chinese), and Wanfang Database (Chinese)
using the following search terms: MMP, “matrix metallopro-
teinase,” and “collagenase” combined with “bladder cancer,”
“bladder carcinoma,” and “polymorphism,” “single nucleotide
polymorphism (SNP),” and “variation” for all study publica-
tions before July 2013, and there was no language restriction in
the literature search. Additional studies were identified by a
hand search of the references of original research, and reviews
were also examined in order to findmore eligible studies. With
regard to published studies of the same author, with overlap-
ping data, we selected the most recent or complete study only.
Inclusion and exclusion criteria
The inclusion criteria of our meta-analysis were as follows: (a)
evaluation of the MMP-1 -1607 1G/2G, MMP-2-1306 C/T,
andMMP-9-1562 C/T polymorphism and bladder cancer risk;
(b) case–control study; (c) provided sufficient genotype data in
order to calculate the odds ratio (OR) with 95 % confidence
interval; (d) genotype frequencies in controls was abided by
Hardy–Weinberg equilibrium (HWE). The following were ex-
clusion criteria: (a) not a case–control study, (b) reviews or case
reports, (c) no available data reported, and (d) duplicated reports.
Data extraction
Two of our authors independently extract the information
from each research report according to the inclusion criteria
listed above. When they have different opinions, they would
reach agreement through discussion. If they cannot reach
consensus, the third author would consulted to resolve the
contradiction. The following information were extracted: (a)
first author's name, (b) publication years, (c) country of origin,
(d) ethnicity, (e) genotyping methods, (f) source of the control
group, (g) sample size of cases and controls, and (h) type of
Table 1 General characteristics of studies included in the meta-analysis







Srivastava [19] 2010 Indian Asian PCR-RFLP PB 200/200 MMP-1-1607
Kader [21] 2006 USA Caucasian Taqman HB 560/560 MMP-1-1607
MMP-2-1306
MMP-9-1562
Tasci [22] 2008 Turkey Caucasian PCR-RFLP PB 102/94 MMP-1-1607
Wieczorek [13] 2013 Poland Caucasian Taqman PB 241/199 MMP-1-1607
MMP-2-1306
MMP-9-1562
Zhong [23] 2005 China Asian PCR-RFLP HB 38/16 MMP-1-1607
MMP-2-1306
MMP-9-1562
PCR–RFLP PCR–restriction fragment length polymorphism, HB hospital based, PB population based
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genotype. We also evaluated whether the genotype distribu-
tions followed the Hardy–Weinberg equilibrium.
Statistical analysis
The possible association between the MMP-1-1607 1G/2G
polymorphism with the risk of bladder cancer was evaluated
by OR and 95 % confidence interval (CI) according to allele
contrast (2G vs. 1G), homozygote (2G2G vs. 1G1G), hetero-
zygote (1G2G vs. 1G1G), recessive (2G2G vs. 1G2G/1G1G),
and dominant (2G2G/1G2G vs. 1G1G) models, while the
strength of association between the MMP-2 -1306 C/T and
MMP-9 -1562 C/T polymorphisms and bladder cancer suscep-
tibility was evaluated by OR and 95 % CI according to allele
contrast (T vs. C), homozygote (TT vs. CC), heterozygote (TC
vs. CC), recessive (TT vs. TC/CC), and dominant (TT/TC vs.
CC) models, respectively. The heterogeneity was tested by a
chi-square-based Q statistic test. The effect of heterogeneity
was quantified by using I2 value as well as P value [24]. If I2
value is >50 % or P <0.10, suggesting that an obvious het-
erogeneity existed, ORs were pooled by random effect model
[25]. Otherwise, the fixed effect model was used [26].
We assessed the HWE for the control group in every article
by using the professional web-based program (http://ihg2.
helmholtz-muenchen.de/cgibin/hw/hwa1.pl), if P >0.05
suggests that the controls followed HWE balance. A
sensitivity analysis was carried out to assess whether there is
stability of our results. By way of deleting a single study, there
was a time to assess whether the study results have an impact
on the overall pooled ORs. [27]. Publication bias was assessed
using Egger’s test (P <0.05 indicates that statistically
significant publication bias existed) [28] and visual
observation of the funnel plot [29]. All statistical tests were
conducted using the Stata Software (version 9.2, Stata Corp).
Results
Search results and study characteristics
A total of five articles [13, 19–23] with 1,141 cases and 1,069
controls were contained in this study after a careful
examination based on the inclusion criteria above, four studies
with 1,103 cases and 1,053 controls forMMP-1 -1607 1G/2G
polymorphism, three studies with 839 cases and 775 controls
for MMP-2 -1306 C/T polymorphism, and three studies with
839 cases and 775 controls for MMP-9-1562 C/T polymor-
phism; the general characteristics of studies included in the
meta-analysis were listed in Table 1. The genotype distribu-
tions in the controls of all studies were consistent with HWE.
Meta-analysis results
The main results of this meta-analysis and the heterogeneity
assessment were shown in Tables 2, 3, and 4. With regard to
MMP-1 -1607 1G/2G polymorphism, significant association
was found with bladder cancer risk only under recessive
model (2G2G vs. 1G2G/1G1G: OR=1.44, 95 % CI=1.05–
1.97, P =0.022, Fig. 1a), and as to MMP-2 -1306 C/T poly-
morphism, significant association was found with bladder
cancer risk only under homozygote model (TT vs. CC: OR=
2.10, 95 % CI=1.38–3.10, P =0, Fig. 1b), but we did not find
any associations between MMP-9-1562 C/T polymorphism
and bladder cancer risk (which only show homozygote model
(TT vs. CC) in Fig. 1c).
Sensitive analysis and publication bias
To estimate the sensitivity of our meta-analysis, a leave-one-
out sensitivity analysis was performed. A single article
Table 2 Results of meta-analysis
for MMP-1-1607 1G/2G poly-
morphism and bladder cancer risk
OR odds ratio, CI confidence in-
terval, F fixed effect model, R
random effect model
Comparison Test of association Model Test of heterogeneity
OR 95 % CI P P I2
2G vs. 1G 1.17 0.98–1.39 0.083 R 0 88.2
2G2G vs. 1G1G 1.26 0.95–1.67 0.103 R 0 83.8
1G2G vs. 1G1G 1.02 0.89–1.16 0.799 R 0.035 65.0
2G2G vs. 1G2G/1G1G 1.44 1.05–1.97 0.022 R 0.003 79.0
2G2G/1G2G vs. 1G1G 1.06 0.95–1.20 0.307 R 0.001 82.8
Table 3 Results of meta-analysis for MMP-2-1306 C/T polymorphism
and bladder cancer risk
Comparison Test of association Model Test of heterogeneity
OR 95 % CI P P I2
T vs. C 1.13 0.71–1.81 0.599 R 0.001 86.4
TT vs. CC 2.10 1.38–3.10 0 F 0.251 27.8
TC vs. CC 1.12 0.64–1.95 0.698 R 0 90.6
TT vs. TC/CC 1.42 0.93–2.16 0.110 F 0.669 0
TT/TC vs. CC 1.11 0.68–1.83 0.679 R 0 90.1
OR odds ratio, CI confidence interval, F fixed effect model, R random
effect model
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included in the meta-analysis was assessed each time to reflect
the impact of the individual data set to pooledORs. Any single
study was omitted, while the overall statistical significance
does not change, indicating that the results are stable (data not
shown). Therefore, the sensitivity analysis results show that
our meta-analysis data is relatively stable and credible.
Both funnel plot and Egger’s test were conducted to access
the publication bias. Funnel plot is relatively straightforward
to observe whether the publication bias is presence, and
Egger’s test was used to provide a statistical evidence of
funnel symmetry. Both the shapes of the funnel plot
(Fig. 1d) and Egger’s test (all P >0.05, data not shown)
suggest that no publication bias existed in our meta-analysis.
Discussion
Bladder cancer is one of the most common urinary malignant
diseases around the world [2]. However, in the incidence of
bladder cancer, the mechanism is not currently clear [5]. There
is growing evidence for the important roles of genetic factors
in the host’s susceptibility to bladder cancer [30–32]. Current-
ly, there are several genetic polymorphisms which have been
identified as risk factors of bladder cancer, such as cyclin D1
(CCND1) G870A polymorphism [10] and NQO1 C609T
polymorphism [33]. There were a series of studies that have
Table 4 Results of meta-analysis for MMP-9-1562 C/T polymorphism
and bladder cancer risk
Comparison Test of association Model Test of heterogeneity
OR 95 % CI P P I2
T vs. C 0.98 0.83–1.15 0.787 F 0.347 5.6
TT vs. CC 1.00 0.55–1.80 0.998 F 0.891 0
TC vs. CC 0.97 0.82–1.15 0.719 F 0.270 23.6
TT vs. TC/CC 1.00 0.55–1.82 0.994 F 0.941 0
TT/TC vs. CC 0.97 0.83–1.14 0.740 F 0.280 21.4
OR odds ratio, CI confidence interval, F fixed effect model, R random
effect model
Fig. 1 a The forest plot describing the meta-analysis under recessive
model for the association between MMP-1-1607 1G/2G polymorphism
and the risk of bladder cancer (2G2G vs. 1G2G/1G1G). b The forest plot
describing the meta-analysis under homozygous model for the associa-
tion between MMP-2-1306 C/T polymorphism and the risk of bladder
cancer (TT vs. CC). c The forest plot describing the meta-analysis under
homozygous model for the association betweenMMP-9-1562 C/T poly-
morphism and the risk of bladder cancer in Chinese population (TT vs.
CC). d Begg funnel plot for publication bias test for the association
between MMP-1 polymorphism and the risk of bladder cancer. Each
point represents a separate study for the indicated association. Log (OR)
natural logarithm of OR. Horizontal line means the effect size
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looked into the association between theMMP polymorphisms
and bladder cancer susceptibility; however, the results obtain-
ed were inconsistent or controversial [13, 19–23].
Meta-analysis is a powerful tool that combines the world’s
research literature that can resolve the statistical power and
discrepancy problem in associated studies [34]. It is a more
systematic statistical method than any single case–control
studies or cohort studies [35, 36], and it may investigate a
large number of individuals, and so, the risk of disease can be
estimated with the impact of a genetic factor on disease
susceptibility [37]. In the current study, a total of five case–
control studies with 1,141 cases and 1,069 controls were
included in the meta-analysis [13, 19–23], and the association
betweenMMP-1 -1607 1G/2G,MMP-2 -1306 C/T, andMMP-
9 -1562 C/T polymorphisms and bladder cancer risk was
explored. Our results suggest thatMMP-1 -1607 1G/2G poly-
morphism was significantly associated with bladder cancer
risk under recessive model, and significant association was
found betweenMMP-2 -1306 C/T polymorphism and bladder
cancer risk under homozygote model, but there is no associ-
ation found between MMP-9 -1562 C/T polymorphism and
bladder cancer risk. The results indicate that potentially func-
tional MMP-1 -1607 1G/2G and MMP-2 -1306 C/T polymor-
phisms may play an important role in the development of
bladder cancer.
In spite of comprehensive analysis conducted to show the
association betweenMMP polymorphisms and bladder cancer
risk, there are still some limitations that should be pointed out.
Firstly, the sample size of each study and the quantity of
studies included in our meta-analysis were relatively small.
The total sample sizemay not be enough tomake a convincing
conclusion. Secondly, there is no uniform definition of the
control group. Some studies used population-based controls,
while others used hospital-based controls, which may not be a
representative of the general population. Thirdly, only pub-
lished studies were included in our meta-analysis, which is
likely to miss some relevant unpublished but may meet the
inclusion criteria articles. Thus, publication bias may be in-
curred. Fourthly, the possible interactions of gene–environ-
ment and gene–gene were not assessed in the meta-analysis.
Therefore, larger-scale and well-designed studies are nec-
essary to estimate the association between MMP polymor-
phisms and the risk of bladder cancer in the future. Besides,
the possible gene–environment and gene–gene interactions
should be considered in the future studies too.
In conclusion, the results of our meta-analysis suggest that
a significant association was found between the MMP-2-1306
C/T and MMP-9-1562 C/T polymorphisms and the risk of
bladder cancer, while theMMP-9 -1562 C/T polymorphism is
not associated with bladder cancer. Considering the limita-
tions listed above, larger-scale and well-designed studies are
require to further estimate the association between MMP
polymorphisms and bladder cancer risk in future studies.
Besides, the possible gene–environment and gene–gene inter-
actions should also be considered in future meta-analysis.
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